December 2nd 2024
If granted, guselkumab will be approved to treat children ages 6 and younger with severe plaque psoriasis and children ages 5 and younger with juvenile psoriatic arthritis.
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis
View More
Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?
View More
Physician perspective on thread lifts
February 1st 2006As might be expected with any new cosmetic procedure, suture suspension, popularly known as "thread lift," has engendered significant media attention. Thread lift has been promoted on "Oprah," "Today" and "Good Morning America" as a "lunch-time facelift." More recently, articles in The New York Times and Allure magazine have questioned the predictability and longevity of results, and the potential for complications.
Biologics may be less toxic than other medications
February 1st 2006National report - Biologic agents will not necessarily be more effective than current drugs used for dermatological conditions, but will produce less toxicities, says the professor and chairman of dermatology at Wake Forest University School of Medicine, Winston-Salem, N. C.
Children in growing numbers suffer from AD
January 1st 2006Baltimore — Currently, 15 percent to 25 percent of children in industrialized countries suffer from atopic dermatitis (AD), representing an increase over the past two to three decades, according to Bernard A. Cohen, M.D., director of pediatric dermatology at Johns Hopkins Children's Center in Baltimore.
Counterfeit drug trade draws congressional scrutiny
December 1st 2005Counterfeit prescription drugs pose a "potentially serious health threat" in the United States — one that can result in serious or deadly consequences for patients because of unscrupulous acts of profiteers who take advantage of a lack of uniform regulation and enforcement.
New pediatric research beacon for larger studies
December 1st 2005Harrison Hot Springs, British Columbia — According to Robert Sidbury, M.D., two of the most important pediatric studies published this year investigated the alleged connection between isotretinoin and depression, thoughts of suicide and even suicide itself among some teenage users being treated for acne.
Counterfeit drug trade draws congressional scrutiny
December 1st 2005Counterfeit prescription drugs pose a "potentially serious health threat" in the United States — one that can result in serious or deadly consequences for patients because of unscrupulous acts of profiteers who take advantage of a lack of uniform regulation and enforcement.
Urticaria: Reviewing the basics
December 1st 2005National report — Categorizing urticaria and following up with effective treatment can prove to be very challenging to the clinician, according to Aniko Kobza Black, M.D., attending physician, St. John's Institute of Dermatology and St. Thomas Hospital, London.